Unlock microscopy-free real-time GPCR internalization with pHSense
pHSense™ probes are optimized reagents for plate readers, specifically designed to study internalization using time-resolved fluorescence (TRF) detection.
They offer high-sensitivity, no-wash detection of internalization events in a scalable, plate-based format. This technology supports robust analysis even at low endogenous receptor expression levels.
-
Suitable for basal/constitutive and agonist-induced GPCR internalization
-
Compatible with TRF plate readers
-
No-wash protocol simplifies workflow
-
Formats available for modified GPCR cell lines or unmodified primary cells
Powered by Revvity’s legacy of innovation in translational science.
Dr. GPCR Ecosystem Partner
Precision Tools for Translational Science
Revvity is a global leader in life science innovation, delivering tools and technologies that bridge the gap between discovery and real-world impact.
With decades of expertise and an unwavering focus on precision, Revvity empowers scientists to simplify complex workflows, accelerate discovery, and drive breakthroughs in drug development, diagnostics, and disease biology.
Whether you’re decoding signaling pathways or designing the next generation of therapeutics, Revvity isn’t just a provider—they’re your partner in discovery.
Discover pHSense™ portfolio
From binding to signaling to internalization: Cell-based fluorescence assays for complete GPCR characterization
The principle of pHSense™ relies on the pH-dependent fluorescence activation of a europium-labeled antibody to monitor receptor internalization in live cells.
-
Neutral pH = low signal: The probe is minimally fluorescent at extracellular neutral pH (≥7), which means it doesn't emit a strong signal when bound to the surface.
-
Internalization into acidic compartments = signal activation: Upon receptor-mediated endocytosis, the probe is internalized into acidic intracellular compartments (like early/late endosomes and lysosomes). The europium complex becomes increasingly fluorescent as the pH drops, enabling dynamic tracking of internalization.
-
Time-Resolved Fluorescence (TRF) = High Signal-to-Background: Europium’s long-lived fluorescence allows TRF detection, which effectively filters out short-lived background signals. This results in high sensitivity and specificity in no-wash, plate-based live-cell assays.
Designed for the detection of FLAG-tagged receptor and membrane protein internalization.
Can be used to label receptors and membrane proteins carrying an extracellular SNAP sequence with a pHSense probe to monitor their internalization
pHSense Fab Anti-Human or Anti-Mouse IgG
Fab fragments for monitoring GPCR and antibody internalization in unmodified cells
The Fab Anti-Human IgG Eu-conjugate can be used in combination with a neutral anti-GPCR to address unmodified receptors in primary cells
The Fab Anti-Mouse IgG2 Eu-conjugate is suited to study mouse biologics targeting GPCR and confirm their internalization effects on receptors.
The pHSense™ Advantage
Clarity. Consistency. Compatibility.
Purpose-Built for Live-Cell Internalization Assays
The pHSense™ family of europium-labeled, pH-sensitive reagents is designed to simplify and accelerate the study of GPCR and membrane protein internalization in live cells.
These reagents are fully compatible with plate-based, no-wash workflows and use time-resolved fluorescence (TRF) to eliminate background noise—delivering clear, quantifiable signals as targets move into acidic intracellular compartments.
What Sets pHSense™ Apart
✅ Time-resolved detection minimizes background noise, which enhances detection sensitivity.
✅ No-wash protocol preserves cell integrity and kinetic detection.
✅ High-throughput ready: faster time-to-results and streamlined data acquisition.
✅ Comprehensive validation: validated for GPCRs, but also antibodies and ADCs.
✅ Versatility across suspension and adherent cells
The Full GPCR Toolkit by Revvity
Every step of the signaling cascade. One trusted source.
GPCRs are among the most powerful and complex targets in biomedical research. Revvity offers a comprehensive reagent portfolio to match that complexity—supporting every stage of the signaling pathway, from ligand binding and G-protein activation to intracellular signaling readouts.
With formats including TR-FRET, radioligand binding, cAMP, IP-One, and phospho-protein assays (ERK, AKT, CREB, MEK), this toolkit is built for speed, reproducibility, and translational insight. Proprietary no-wash technologies help reduce hands-on time while maintaining exceptional data quality—so you can move fast without compromise.
Explore Revvity’s GPCR Assay Technologies
Tools designed to illuminate every step of GPCR signaling—from binding to downstream response.
Ligand binding
Measure receptor engagement with high sensitivity using TR-FRET, radioligand, and Fluorescent Tag-lite® formats.
G-Protein Activation
Quantify Gs, Gi, and Gq activation in real time with cAMP, GTP, and IP-One assays.
Arrestin Recruitment
Detect β-arrestin recruitment with TR-FRET and luminescence assays tailored for biased signaling studies.
Intracellular Signaling
Track key downstream events like ERK, AKT, and CREB phosphorylation with high-throughput precision.
Meet the Team behind pHSense™
Eric TRINQUET
Sr Director Life Sciences Reagents, Revvity
Eric Trinquet is a recognized expert in the field of immunoassays and fluorescence technologies. He currently leads Revvity's Research and Development activities, focusing on biochemical and cellular assay platforms related to Life Sciences Reagents.
Before joining Revvity, Eric worked for Cisbio Bioassays first as Director of Technological Development and then as R&D Director. His career is marked by significant contributions, from introducing HTRF technology in the field of high-throughput screening to developing innovative solutions such as the IP-One kit for studying G Protein-Coupled Receptors (GPCRs) and the Tag-lite platform.
Elodie DUPUIS
R&D Senior project manager, team leader.
Elodie Dupuis earned her Master’s degree in biology and biotechnology engineering from the University of Sciences of Nîmes and the Ecole des Mines engineering school (France) in 2009. She then joined Cisbio Bioassays, and later Revvity, as project leader and team manager in the Research & Development department, leading her team on the development of innovative HTRF™ and AlphaLISA™ kits for pharma, biotech, and academic partners. Through her research contributions, she has co-authored numerous scientific publications and holds several patents as an inventor. She has been leading collaborative projects with public research institutes and pharmaceutical companies, most notably the joint Revvity/Institute of Functional Genomics team, EIDOS.
In 2020, together with her team, she initiated a long-term research effort that enabled the creation of a new and innovative portfolio for GPCRs, antibody drug conjugates, and several other applications: pHSense™. 2025 marked the commercial launch of the first pHSense products by Revvity.
Mathis LAFFENETRE
Product Manager, Immunoassay Reagents.
Mathis holds a biotechnology engineering degree from the National School of Biomolecule Technology of Bordeaux and an MS in biomedical business management from the Grenoble School of Management.
He joined Revvity (then Cisbio) in 2016 as part of the scientific marketing effort to build brand recognition for the HTRF technology and accelerate the company’s reagents use in academic labs, biotech companies, and pharma.
In the following years, he held several marketing and strategic positions in France and the US, primarily related to the Immunoassay portfolio. As of 2025, he is part of the Immunoassay & Imaging Reagents Portfolio group as a product manager for the GPCRs, and is responsible for supporting the adoption and expansion of the reagent portfolio into the hands of scientists and researchers.
Inside the Science: A Conversation with Revvity's Dr. Eric Trinquet
From Rare Earth Probes to Internalization Assays: The pH Sense Story
If you’ve ever used HTRF or wondered what goes into making a product worthy of your next experiment, this is your backstage pass.
Our Partnership
Dr. GPCR Spotlights Revvity’s pHSense™ Reagents for Real-Time GPCR Internalization
A new reagent family designed to unlock high-throughput internalization workflows—now featured across the Dr. GPCR Ecosystem
Boston, MA – September 2025 — Dr. GPCR, the global nonprofit platform dedicated to advancing GPCR research and drug discovery, is proud to spotlight the launch of pHSense™, a new reagent family from Revvity designed to bring unprecedented clarity, speed, and scalability to the study of receptor internalization.
Internalization is a core—but often overlooked—dimension of GPCR biology. Traditionally, studying it has meant long workflows, low throughput, or expensive imaging platforms. pHSense™ changes that by combining europium-based, pH-sensitive probes with no-wash, live-cell protocols and TRF-based detection—making it possible to monitor internalization in real time, in standard plate-based assays.
“When we saw dose-dependent internalization in endogenous GLP1R cells—without microscopy—that was the turning point,” said Dr. Eric Trinquet, Director of Research and Development at Revvity. “We knew pHSense could offer something truly new to the GPCR field.”
A Tool Designed for Real Research Needs
Built on more than two decades of GPCR assay innovation, pHSense™ was developed to overcome three persistent barriers in internalization studies:
-
Complexity of imaging-based workflows
-
Lack of scalability for high-throughput screening
-
Difficulty detecting endogenous receptor activity
With pHSense™, scientists can finally move beyond proxy readouts and track GPCR internalization as it happens—even at physiological expression levels. All four formats are validated in well-established models like GLP1R and Mu opioid receptor (MOR), and are compatible with HTRF plate readers already used in most labs.
Related Articles
